Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have received an average recommendation of “Moderate Buy” from the eight analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $55.50.

Several research analysts have recently weighed in on TVRD shares. Lucid Cap Mkts raised shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. Weiss Ratings reissued a “sell (e)” rating on shares of Tvardi Therapeutics in a research note on Monday, December 29th. Finally, Wall Street Zen upgraded Tvardi Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, March 8th.

Tvardi Therapeutics Trading Down 0.6%

Shares of NASDAQ:TVRD opened at $3.18 on Friday. The company has a 50 day moving average of $3.81 and a 200 day moving average of $9.00. The stock has a market cap of $29.83 million, a P/E ratio of -0.33 and a beta of 0.14. Tvardi Therapeutics has a 12 month low of $3.05 and a 12 month high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its earnings results on Tuesday, March 31st. The company reported ($0.78) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Arax Advisory Partners increased its position in shares of Tvardi Therapeutics by 277.2% in the fourth quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock worth $36,000 after purchasing an additional 6,173 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in Tvardi Therapeutics during the second quarter valued at approximately $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Tvardi Therapeutics in the 2nd quarter worth approximately $43,000. HRT Financial LP purchased a new position in Tvardi Therapeutics in the 4th quarter worth approximately $47,000. Finally, XTX Topco Ltd bought a new position in shares of Tvardi Therapeutics in the 4th quarter worth $55,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.